Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Core Insights - Protara Therapeutics reported significant progress in 2025, particularly with positive interim results from the ADVANCED-2 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) [2][5] - The company plans to initiate the THRIVE-3 Phase 3 clinical trial for IV Choline Chloride in Q3 2025, targeting patients on parenteral support [4][5] - Protara's financial results for Q1 2025 show a net loss of $11.9 million, with cash reserves expected to support operations into 2027 [14][24] Recent Progress and Highlights - TARA-002 demonstrated a complete response (CR) rate of 100% in BCG-Unresponsive patients and 76% in BCG-Naïve patients during the ADVANCED-2 trial [6] - The company expects to announce interim results from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025 [5][6] - Leadership team strengthened with key appointments, including Dr. Leonardo Viana Nicacio as Chief Medical Officer [9] Financial Overview - As of March 31, 2025, Protara had cash, cash equivalents, and investments totaling $158 million, sufficient to fund operations into 2027 [5][14] - Research and development expenses increased to $9.1 million in Q1 2025 from $7.7 million in the prior year, primarily due to clinical trial activities [14][24] - General and administrative expenses rose to $5.0 million in Q1 2025 from $4.1 million in the prior year [14][24] Product Development - TARA-002 is being evaluated for NMIBC and lymphatic malformations (LMs), with ongoing trials expected to yield interim updates in the second half of 2025 [8][11] - IV Choline Chloride is positioned as a potential first FDA-approved IV choline formulation for patients on parenteral nutrition [16] - The company continues to explore combination treatments and dosing strategies for TARA-002 in NMIBC patients [6][12]